---
schema_version: "secwatch.filing_event.v1"
accession: "0001411685-25-000007"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:52:08.169410+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vistagen announces positive Phase 2A results for PH284 in cancer cachexia; 71% hunger improvement

## Summary
- PH284 nasal spray demonstrated 71% improvement in subjective feeling of hunger before dinner on Day 7 vs <1% for placebo.
- No serious adverse events; adverse events similar to placebo and attributed to underlying cancer, not treatment.
- PH284 is fifth pherine product candidate in Vistagen's neuroscience pipeline with a positive efficacy signal.
- Study enrolled 40 female patients with cachexia due to terminal cancer; double-blind, placebo-controlled design.

## SEC filing metadata
- accession: 0001411685-25-000007
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000007/0001411685-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000007/vtgn-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411685-25-000007
- JSON: https://secwatch.observer/filing/0001411685-25-000007.json
- Plain text: https://secwatch.observer/filing/0001411685-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.